ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1354

Whipple’s Disease: The Diagnostic Utility of Synovial Fluid Tropheryma Whipplei Polymerase Chain Reaction

Zoran Kvrgic1, Kelly Cawcutt2, Robin Patel3, Abinash Virk2, Clement J. Michet Jr.4, Eric L. Matteson5 and Tim Bongartz1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Infectious Diseases, Mayo Clinic, Rochester, MN, 3Medicine, Mayo Clinic, Rochester, MN, 4Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Bacterial infections, Diagnostic Tests, inflammatory arthritis, polymerase chain reaction (PCR) and synovial fluid

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Infection-related Rheumatic Disease: Poster Session

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Inflammatory arthritis is a common, non-specific symptom of Whipple’s disease. Recovery of the organism by conventional culture is often unsuccessful. Synovial fluid polymerase chain reaction (PCR) testing for Tropheryma whippelii may increase the diagnostic yield; however the diagnostic specificity of this approach is unclear. A high rate of detection of T. whipplei PCR in saliva of healthy individuals has been reported. To date, there has been no study of the performance of PCR for T. whippelii in synovial fluid PCR.

Therefore, we aimed to summarize our experience with a T. whippelii synovial fluid PCR test in patients seen at a single referral center and clarify whether utilization of this test in patients with inflammatory arthritis would result in a high rate of false-positive results.

Methods:

DNA was extracted from synovial fluid using the automated MagNA Pure LC instrument. Real-time PCR with FRET probe detection, targeting the heat shock protein gene of T. whipplei, was performed on amplified DNA. The total number of patients who had synovial fluid PCR testing for T. whippelii between 01/01/2003-04/01/2015 was determined using the clinical microbiology database. A detailed chart review was performed for all patients with positive PCR results. All patients were followed up for a minimum of one year.

Results:

Over the past 12 years, 302 patients underwent synovial fluid PCR testing for T. whippelii at our institution. The PCR was positive in only 4 patients.  All PCR positive patients were middle-aged males who presented with chronic inflammatory arthritis and a variety of additional symptoms including fever, malaise, and peripheral edema and generalized weakness. They had been diagnosed and treated with various immunosuppressive drugs or antiinflammatories unsuccessfully. Small bowel biopsy to identify the organism was undertaken in 2 of the 4 patients with positive synovial fluid PCR. Tissue samples from these biopsies were negative for periodic acid Schiff stain (PAS) positive macrophages and by T. whippelii PCR.

All synovial fluid PCR positive patients (including the 2 with negative small bowel biopsies) were diagnosed with Whipple’s disease by their medical team and subsequently treated with antibiotics (ceftriaxone 2g IV q24 for 2-4 weeks followed by trimethoprim-sulfamethoxazole 160/800 mg 1 tablet twice daily for 1 year), resulting in complete resolution of symptoms in all patients. No recurrences occurred during the follow-up period of at least 1 year.

Conclusion:

Our experience suggests that T. whippelii synovial fluid PCR testing in patients with inflammatory arthritis is a highly specific test for Whipple’s disease. All patients who tested positive in our cohort had symptoms consistent with a diagnosis of Whipple’s disease, had previously been unsuccessfully treated with immunosuppressive therapies, and had a dramatic and complete improvement after starting antibiotic therapy. No recurrences/alternative diagnoses emerged during the follow-up period. Synovial fluid PCR testing for T. whippelii appears to be a valuable diagnostic test in patients with inflammatory arthritis and suspected Whipple’s disease even when the stain for PAS positive macrophages on small bowel biopsy is negative.


Disclosure: Z. Kvrgic, None; K. Cawcutt, None; R. Patel, None; A. Virk, None; C. J. Michet Jr., None; E. L. Matteson, None; T. Bongartz, None.

To cite this abstract in AMA style:

Kvrgic Z, Cawcutt K, Patel R, Virk A, Michet CJ Jr., Matteson EL, Bongartz T. Whipple’s Disease: The Diagnostic Utility of Synovial Fluid Tropheryma Whipplei Polymerase Chain Reaction [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/whipples-disease-the-diagnostic-utility-of-synovial-fluid-tropheryma-whipplei-polymerase-chain-reaction/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/whipples-disease-the-diagnostic-utility-of-synovial-fluid-tropheryma-whipplei-polymerase-chain-reaction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology